Retina Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Retina. 2014 Apr;34(4):781-4. doi: 10.1097/IAE.0b013e3182a2f523.
To assess the overall risk of needlestick injuries (NSIs) associated with intravitreal injection, and more specifically related to the practice of compounding pharmacies of applying informational adhesive stickers to repackaged bevacizumab injection syringes.
This cross-sectional study involved an online survey of retina specialists in the United States.
Of the 717 invited retina specialists, 158 (22%) responded to the online survey. The respondents reported using 1 pair of gloves (51%), no gloves (46%), or 2 pairs of gloves (3%) during intravitreal injection. Repackaged bevacizumab syringes distributed by compounding pharmacy were used by 89% of the respondents, and 63% reported that the adhesive sticker was applied directly to the syringe. Unintentional adhesion between the sticker and hand or glove was experienced by 9% of respondents. At least 1 NSI during intravitreal injection was experienced by 8% of respondents, and sticker-related injury was reported by 3%. The sticker was perceived to increase risk for NSI by 33% of respondents.
This survey showed that 8% of the responding physicians surveyed have experienced at least one NSI during intravitreal injections, of which approximately one third was attributed to the adhesive sticker. Direct application of misfitting stickers to repackaged syringes by compounding pharmacies may be a practice that can aggravate the risk of NSI.
评估与玻璃体腔内注射相关的针刺伤（NSI）总体风险，特别是与重新包装贝伐单抗注射注射器的复合药房实施信息性粘性标签相关的风险。
这项横断面研究涉及对美国视网膜专家的在线调查。
在 717 名受邀的视网膜专家中，有 158 名（22%）对在线调查做出了回应。受访者报告在玻璃体腔内注射期间使用 1 副手套（51%）、不使用手套（46%）或使用 2 副手套（3%）。89%的受访者使用了由复合药房分发的重新包装的贝伐单抗注射器，并且 63%的受访者报告说粘性标签直接贴在注射器上。9%的受访者经历过标签与手或手套之间的意外粘连。8%的受访者报告至少在玻璃体腔内注射期间发生过 1 次 NSI，并且有 3%的受访者报告了与标签相关的伤害。33%的受访者认为标签会增加 NSI 的风险。
这项调查显示，接受调查的医生中有 8%在玻璃体腔内注射期间至少经历过一次 NSI，其中约三分之一归因于粘性标签。复合药房直接将不合适的标签贴在重新包装的注射器上，可能会加剧 NSI 的风险。
